We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Pennsylvania-based drug company Mylan Laboratories could try to capitalize on its first-to-file status for Pfizer's blood-pressure drug Norvasc by launching during the pediatric exclusivity period, according to one analyst.
The marketing application for high blood pressure treatment Rasilez, manufactured by Swiss drugmaker Novartis, has been accepted for review by the U.S. FDA, the company reported.
India-based Biocon Biopharmaceutical has invested $10 million for its cell-culture fermentation and aseptic unit for the development of autoimmune, metabolic and anticancer drugs, the company reported.
Clinical Data, Inc., a worldwide leader in providing comprehensive molecular and pharmacogenomics services as well as clinical diagnostics to improve patient care, announced today that its PGxHealth division has completed the validation of a genetic marker that will help identify patients at risk for Clozapine-Induced Agranulocytosis (CIA), a potentially deadly blood disorder.
Bradmer Pharmaceuticals Inc., a biotechnology company dedicated to the development and commercialization of cancer therapies, has signed a three-year contract with MDS Nordion for the formulation development and clinical trial supply of Neuradiab in preparation for the planned multi-center clinical trial.